Braidwell’s Crescent Biopharma CBIO Stock Holding History

Braidwell’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-261,504	Closed	-$4.22M	–	77
2025 Q2	$4.22M	Buy	+261,504	New	+$5.53M	0.14%	51

Other funds holding CBIO

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Braidwell's CBIO Position: Q3 2025 in Review

Braidwell sold out of Crescent Biopharma (CBIO) in Q3 2025, closing a stake of 261,504 shares — an estimated $4.22M sold.

Braidwell first reported a position in CBIO in Q2 2025 and held it in 1 quarter. The position peaked at $4.22M in Q2 2025. 41 funds tracked by Wall St. Rank hold CBIO as of Q3 2025.

Braidwell reported no remaining Crescent Biopharma position as of Q3 2025 after selling out during the quarter.
Braidwell sold 261,504 Crescent Biopharma shares in Q3 2025, an estimated $4.22M.
Braidwell first reported a position in Crescent Biopharma in Q2 2025 and held it in 1 quarter.
Braidwell's Crescent Biopharma position peaked at $4.22M in Q2 2025.
41 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2025.

Based on Braidwell's 13F filing for Q3 2025, filed 14 Nov 2025.